Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert E Ratner

Showing results (61-70 of 87) with videos related to

Pageof 9
Sort By:
Endocrine Research|April 17, 2026
Broad-Spectrum Effects of Carbohydrate Reduction on Inflammatory and Immune Mediators in Type 2 DiabetesShaminie J Athinarayanan, Stephen D Phinney, Rebecca N Adams, et al.
Diabetes Care|August 8, 2007
Resolution of asymptomatic myocardial ischemia in patients with type 2 diabetes in the Detection of Ischemia in Asymptomatic Diabetics (DIAD) studyFrans J Th Wackers, Deborah A Chyun, Lawrence H Young, et al.
JAMA|April 16, 2009
Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trialLawrence H Young, Frans J Th Wackers, Deborah A Chyun, et al.
Journal of the American College of Cardiology|December 20, 2008
Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trialJerome L Fleg, Mihriye Mete, Barbara V Howard, et al.
Circulation|March 3, 2010
Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history trialHertzel C Gerstein, Robert E Ratner, Christopher P Cannon, et al.
American Journal of Nephrology|December 20, 2003
Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathyW Kline Bolton, Daniel C Cattran, Mark E Williams, et al.
Diabetes Care|July 28, 2004
Detection of silent myocardial ischemia in asymptomatic diabetic subjects: the DIAD studyFrans J Th Wackers, Lawrence H Young, Silvio E Inzucchi, et al.
The Journal of Clinical Endocrinology and Metabolism|March 17, 2016
Diabetes Incidence and Glucose Tolerance after Termination of Pioglitazone Therapy: Results from ACT NOWDevjit Tripathy, Dawn C Schwenke, MaryAnn Banerji, et al.
Journal of Clinical Lipidology|February 18, 2010
PREVENTION OF ATHEROSCLEROSIS WITH LDL-C LOWERING - LIPOPROTEIN CHANGES AND INTERACTIONS: THE SANDS STUDYWm James Howard, Marie Russell, Jerome L Fleg, et al.
Diabetes Care|April 8, 2014
Baseline adiponectin levels do not influence the response to pioglitazone in ACT NOWDevjit Tripathy, Stephen C Clement, Dawn C Schwenke, et al.
Pageof 9

Showing results (61-70 of 87) with videos related to

Sort By:
Pageof 9
Endocrine Research|April 17, 2026
Broad-Spectrum Effects of Carbohydrate Reduction on Inflammatory and Immune Mediators in Type 2 DiabetesShaminie J Athinarayanan, Stephen D Phinney, Rebecca N Adams, et al.
Diabetes Care|August 8, 2007
Resolution of asymptomatic myocardial ischemia in patients with type 2 diabetes in the Detection of Ischemia in Asymptomatic Diabetics (DIAD) studyFrans J Th Wackers, Deborah A Chyun, Lawrence H Young, et al.
JAMA|April 16, 2009
Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trialLawrence H Young, Frans J Th Wackers, Deborah A Chyun, et al.
Journal of the American College of Cardiology|December 20, 2008
Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trialJerome L Fleg, Mihriye Mete, Barbara V Howard, et al.
Circulation|March 3, 2010
Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history trialHertzel C Gerstein, Robert E Ratner, Christopher P Cannon, et al.
American Journal of Nephrology|December 20, 2003
Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathyW Kline Bolton, Daniel C Cattran, Mark E Williams, et al.
Diabetes Care|July 28, 2004
Detection of silent myocardial ischemia in asymptomatic diabetic subjects: the DIAD studyFrans J Th Wackers, Lawrence H Young, Silvio E Inzucchi, et al.
The Journal of Clinical Endocrinology and Metabolism|March 17, 2016
Diabetes Incidence and Glucose Tolerance after Termination of Pioglitazone Therapy: Results from ACT NOWDevjit Tripathy, Dawn C Schwenke, MaryAnn Banerji, et al.
Journal of Clinical Lipidology|February 18, 2010
PREVENTION OF ATHEROSCLEROSIS WITH LDL-C LOWERING - LIPOPROTEIN CHANGES AND INTERACTIONS: THE SANDS STUDYWm James Howard, Marie Russell, Jerome L Fleg, et al.
Diabetes Care|April 8, 2014
Baseline adiponectin levels do not influence the response to pioglitazone in ACT NOWDevjit Tripathy, Stephen C Clement, Dawn C Schwenke, et al.
Pageof 9